文献速递妇科产科

美国低与高疫苗接种覆盖率人群中HPV基因型流行率比较

HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay.
PubMed 文献 · Gynecol Oncol · 2026-03-04

该研究比较了美国低接种覆盖率人群(2013-2014年Onclarity筛查试验)与高接种覆盖率人群(2021-2023年三个临床实验室真实世界筛查)的HPV基因型流行率及≥CIN2结果,按21-29、30-39和≥40岁分层。结果显示高覆盖率人群中21-29岁和30-39岁者HPV16/18流行率显著降低,但21-29岁组其他12种基因型流行率及任何HPV总体流行率显著升高。结论认为疫苗接种同时影响疫苗型和非疫苗型流行率,对宫颈癌筛查有重要意义。

要点

  • 高接种覆盖率人群21-29岁HPV16/18流行率2.3% vs 低覆盖率5.4%(p<0.001)。
  • 高覆盖率人群21-29岁其他12种基因型流行率29.8% vs 22.2%(p<0.001)。
  • 高覆盖率人群21-29岁任何HPV总体流行率31.1% vs 25.4%(p<0.001)。

核心结论

  • HPV疫苗接种显著降低疫苗型流行率,同时某些非目标型流行率升高,形成动态平衡,对宫颈癌筛查和未来宫颈疾病发生率有重要影响。

研究设计与样本

  • 低覆盖率数据来自美国Onclarity宫颈癌筛查试验(2013-2014年),高覆盖率数据来自三个临床实验室的真实世界筛查(2021-2023年),按21-29、30-39和≥40岁分层比较基因型流行率及≥CIN2结果。

主要发现

  • 高覆盖率人群21-29岁HPV16/18流行率为2.3%,低覆盖率人群为5.4%(p<0.001)。
  • 高覆盖率人群30-39岁HPV16/18流行率为2.5%,低覆盖率人群为3.6%(p<0.001)。
  • 高覆盖率人群21-29岁其他12种基因型流行率为29.8%,低覆盖率人群为22.2%(p<0.001)。
  • 高覆盖率人群21-29岁任何HPV总体流行率为31.1%,低覆盖率人群为25.4%(p<0.001)。

临床怎么用

  • 在宫颈癌筛查中应关注疫苗接种后非目标HPV基因型流行率升高的可能性,并据此评估筛查策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: HPV vaccination is an effective strategy for reducing both HPV infection and cervical disease. In the USA, vaccination with the 4-valent HPV vaccine (Merck) has led to a significant reduction in target genotypes HPV16 and 18. However, recent work suggests that vaccination can result in prevalence changes of HPV genotypes not targeted by vaccination (non-vaccine target types). Here we compared genotype prevalence results and HPV-associated cervical intraepithelial neoplasia grade 2 or worse (≥CIN2) results from low- and high-vaccine coverage USA populations. METHODS: Low-coverage vaccine population HPV genotype and ≥ CIN2 information was obtained from the Onclarity cervical cancer screening trial (USA; 2013-2014); high-coverage vaccine population data were collected across three clinical laboratories as part of real-world cervical cancer screening (USA; 2021-2023). Data were stratified into age groups: 21-29 (highest proportion of vaccinated individuals), 30-39, and ≥ 40 years. RESULTS: HPV16/18 genotype prevalence was significantly lower in the high-coverage population for individuals aged 21-29 years (2.3% versus 5.4%; p < 0.001) and 30-39 years (2.5% versus 3.6%; p < 0.001), whereas the prevalence of the Other 12 genotypes was significantly higher (29.8% versus 22.2%; p < 0.001) in the 21-29-year age group only. The overall prevalence of any HPV was higher in the high-coverage populations for the 21-29-year age group (31.1% versus 25.4%; p < 0.001). CONCLUSIONS: HPV vaccination is significantly impacting both vaccine and non-vaccine type prevalence, reducing the incidence of vaccine types with concomitant increase of certain non-target types. This apparent dynamic equilibrium has important implications for cervical cancer screening and future incidence of cervical disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Morel D, Parvu V, Andrews J, et al. HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay. Gynecol Oncol. 2026. PMID: 41785531. doi:10.1016/j.ygyno.2026.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。